NasdaqGS:VIRBiotechs
Vir Biotechnology (VIR) Stock Could Be 56% Undervalued After New PSMA Data
Clinical PSMA Data Sparks Fresh Look At Vir Biotechnology Stock
Vir Biotechnology (VIR) has moved back onto investors' radars after new PSMA clinical data in prostate cancer prompted an updated investment thesis and renewed focus on the company’s T cell engager pipeline.
See our latest analysis for Vir Biotechnology.
At a share price of US$9.16, Vir Biotechnology’s short term picture reflects a mix of optimism and caution, with a 7 day share price return of 6.39% and a year to date share...